Risk Factors of Chronic Kidney Disease in Chronic Hepatitis B: A Hospital-based Case-control Study from China

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2022 May 9

PMID 35528983

Authors

Yunqi Liu

Ximei Wang

Fuping Xu

Dengren Li

Huimin Yang

Nan Sun

Yu-Chen Fan

Xiangdong Yang

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Chronic kidney disease (CKD) usually occurs during the chronic infection of hepatitis B virus (HBV). However, the risk factors of CKD in an HBV population have not been completely demonstrated. Our present study aimed to investigate the risk factors of CKD in chronic HBV infection using a hospital based cross-sectional study in the northern area of China.

Methods: During January 2013 to December 2017, a total of 94 patients with CKD complicated by chronic HBV infection were consecutively enrolled in the study, as well as 548 age- and sex-matched hepatitis B patients without CKD who were enrolled as controls. Univariate and multivariate regression analyses were used to determine the effects of each variable after adjusting for cofounding factors.

Results: Multivariate analysis showed that HBeAg-positive status (odds ratio [OR]=2.099, 95% CI 1.128-3.907), dyslipidemia (OR: 3.025, 95% CI 1.747-5.239), and hypertension (OR: 12.523, 95% CI 6.283-24.958) were independently associated with the incidence of CKD, while duration of HBV infection (≥240 months) (OR: 0.401, 95% CI 0.179-0.894), Log HBsAg (OR: 0.514, 95% CI 0.336-0.786), and coronary heart disease (OR: 0.078, 95% CI 0.008-0.768) were protective factors for the incidence of CKD. Duration of HBV infection, Log HBsAg, HBeAg-positive status and dyslipidemia remained the risk factors for CKD after adjusting for diabetes mellitus, hypertension, and coronary heart disease.

Conclusions: Duration of HBV infection, Log HBsAg, HBeAg-positive status and dyslipidemia contributed to the incidence of CKD during chronic HBV infection in a Chinese population.

Citing Articles

Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments.

Hu Y, Zhang Y, Jiang W Clin Exp Med. 2025; 25(1):57.

PMID: 39954162 PMC: 11829913. DOI: 10.1007/s10238-025-01584-4.

Hepatitis B virus infection as a risk factor for chronic kidney disease: a systematic review and meta-analysis.

Chen D, Yu R, Yin S, Qiu W, Fang J, Peng X BMC Infect Dis. 2024; 24(1):620.

PMID: 38909191 PMC: 11193185. DOI: 10.1186/s12879-024-09546-z.

Liver fibrosis MR images classification based on higher-order interaction and sample distribution rebalancing.

Zhang L, Xiao Z, Jiang W, Luo C, Ye M, Yue G Health Inf Sci Syst. 2023; 11(1):51.

PMID: 37954065 PMC: 10632346. DOI: 10.1007/s13755-023-00255-6.

Screening for renal impairment in viral hepatopathy B: it is time to begin.

Boudabbous M, Bouzid F, Agrebi I, Gdoura H, Chtourou L, Moalla M Future Sci OA. 2023; 9(9):FSO886.

PMID: 37752918 PMC: 10518828. DOI: 10.2144/fsoa-2023-0019.

References

Wang S, Tao Y, Tao Y, Jiang J, Yan L, Wang C . Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study. BMC Public Health. 2018; 18(1):1088. PMC: 6122542. DOI: 10.1186/s12889-018-5984-6. View

Izzedine H, Launay-Vacher V, Deray G . Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005; 45(5):804-17. DOI: 10.1053/j.ajkd.2005.02.010. View

Kupin W . Viral-Associated GN: Hepatitis B and Other Viral Infections. Clin J Am Soc Nephrol. 2016; 12(9):1529-1533. PMC: 5586580. DOI: 10.2215/CJN.09180816. View

Wang K, Wu Z, Ye Y, Liu J, Zhang G, Su Y . Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Hepat Mon. 2014; 14(7):e19370. PMC: 4139694. DOI: 10.5812/hepatmon.19370. View

Chan T . Hepatitis B and Renal Disease. Curr Hepat Rep. 2010; 9(2):99-105. PMC: 2861764. DOI: 10.1007/s11901-010-0042-6. View

Sarin S, Kedarisetty C, Abbas Z, Amarapurkar D, Bihari C, Chan A . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2015; 8(4):453-71. DOI: 10.1007/s12072-014-9580-2. View

Chamberlain J, Rhinehart A, Shaefer Jr C, Neuman A . Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2016; 164(8):542-52. DOI: 10.7326/M15-3016. View

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

Amet S, Bronowicki J, Thabut D, Zoulim F, Bourliere M, Mathurin P . Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int. 2014; 35(1):148-55. DOI: 10.1111/liv.12480. View

10.

Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J . Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55. DOI: 10.1016/S0140-6736(15)61412-X. View

11.

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

12.

McClellan W, Flanders W . Risk factors for progressive chronic kidney disease. J Am Soc Nephrol. 2003; 14(7 Suppl 2):S65-70. DOI: 10.1097/01.asn.0000070147.10399.9e. View

13.

Sun Y, Fan Y, Wang N, Hua-Xiang Xia H, Xiao X, Wang K . Increased A20 mRNA Level in Peripheral Blood Mononuclear Cells is Associated With Immune Phases of Patients With Chronic Hepatitis B. Medicine (Baltimore). 2015; 94(52):e2428. PMC: 5291645. DOI: 10.1097/MD.0000000000002428. View

14.

Wang L, Fan Y, Zhao J, Gao S, Sun F, Han J . Elevated expression of tumour necrosis factor-α-induced protein 8 (TNFAIP8)-like 2 mRNA in peripheral blood mononuclear cells is associated with disease progression of acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2013; 21(1):64-73. DOI: 10.1111/jvh.12116. View

15.

Bhimma R, Coovadia H . Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004; 24(2):198-211. DOI: 10.1159/000077065. View

16.

Wang Z, Fayngerts S, Wang P, Sun H, Johnson D, Ruan Q . TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A. 2012; 109(38):15413-8. PMC: 3458374. DOI: 10.1073/pnas.1204525109. View

17.

Chen Y, Su Y, Li C, Wu C, Lee M . A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2014; 87(5):1030-8. DOI: 10.1038/ki.2014.363. View

18.

Neumann K, Arzt M, Heid I, Boger C, Stadler S . Sleep-Disordered Breathing Is Associated with Metabolic Syndrome in Outpatients with Diabetes Mellitus Type 2. J Diabetes Res. 2019; 2019:8417575. PMC: 6501158. DOI: 10.1155/2019/8417575. View

19.

Fabrizi F, Messa P, Basile C, Martin P . Hepatic disorders in chronic kidney disease. Nat Rev Nephrol. 2010; 6(7):395-403. DOI: 10.1038/nrneph.2010.37. View

20.

dos Santos D, Neves P, Azeredo E, Pelajo-Machado M, Martinho J, Pacheco-Moreira L . Activated lymphocytes and high liver expression of IFN-γ are associated with fulminant hepatic failure in patients. Liver Int. 2011; 32(1):147-57. DOI: 10.1111/j.1478-3231.2011.02654.x. View